Entera Bio Ltd. (ENTX) stock
ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.26+0.26 (+8.67%)
Close on Nov 18, 2026Market cap $564.44MP/E –Yield –
Entera Bio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Entera Bio's revenue for the twelve months ending Jun 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was $42.00K, down 76.8% from the year before. The highest annual figure on record is $571.00K in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.00K | -76.8% |
| FY2024 | Dec 31, 2024 | $181.00K | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $134.00K | -76.5% |
| FY2021 | Dec 31, 2021 | $571.00K | +56.4% |
| FY2020 | Dec 31, 2020 | $365.00K | +54.7% |
| FY2019 | Dec 31, 2019 | $236.00K | -52.8% |
| FY2018 | Dec 31, 2018 | $500.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $42.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $82.00K | – |
| Q3 FY2024 | Sep 30, 2024 | $42.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $57.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $14.00K | -91.5% |
| Q3 FY2022 | Sep 30, 2022 | $8.00K | -94.3% |
| Q2 FY2022 | Jun 30, 2022 | $44.00K | -59.6% |
| Q1 FY2022 | Mar 31, 2022 | $68.00K | -56.7% |
| Q4 FY2021 | Dec 31, 2021 | $165.00K | +217.3% |
| Q3 FY2021 | Sep 30, 2021 | $140.00K | +89.2% |
| Q2 FY2021 | Jun 30, 2021 | $109.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $157.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $52.00K | – |
| Q2 FY2019 | Jun 30, 2019 | $74.00K | – |
See a number that looks wrong?